Please login to the form below

Not currently logged in
Email:
Password:

Sandoz

This page shows the latest Sandoz news and features for those working in and with pharma, biotech and healthcare.

Novartis follows Pfizer and freezes US prices this year

Novartis follows Pfizer and freezes US prices this year

There were also strong gains for the emerging Sandoz biosimilars franchise, which grew by a third to $363m in the first six months of the year, driven by Rixathon(rituximab) and ... However, sales at Sandoz were flat overall as pricing pressure pegged

Latest news

More from news
Approximately 17 fully matching, plus 186 partially matching documents found.

Latest Intelligence

  • Building a bright future Building a bright future

    Mylan’s biosimilar of the multiple sclerosis injection therapy copaxane is not gliding to the promised land, and delays have given rivals Momenta and Novartis’Sandoz a tilt at the

  • Deal Watch November 2016 Deal Watch November 2016

    In May this year Sandoz announced that a regulatory submission for its version of rituximab had been accepted by the EMA following multiple clinical trials in over 800 patients.

  • Deal Watch October 2016 Deal Watch October 2016

    Even without non-exclusive deals from one supplier, there is the additional competitive risk of new biosimilar entrants, such as Sandoz, etcetera.

  • Can biosimilars live up to the hype? Can biosimilars live up to the hype?

    There are a lot of things to be very proud of in Europe,” says Carol, who is also global head biopharmaceuticals and oncology injectables at Sandoz. “ ... More than 700 biosimilars are being developed around the world with Sandoz on target for ten

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    The biosimilars under development by companies such as Sandoz, Amgen and Boehringer-Ingelheim may not be an immediate threat but together they have the potential to severely impact the company's ... Having long lagged behind its European counterparts,

More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 17 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics